URGN: Future Profit Margins Will Improve Through New J Code Reimbursement
AnalystConsensusTarget has maintained UroGen Pharma's fair value at $35.63, reflecting modest adjustments to their valuation model rather than a significant change in outlook. Bullish analysts see a constructive risk-reward setup, while bearish analysts recommend caution due to ongoing review of profitability and scale. Recent news includes positive Phase 3 trial results for ZUSDURI, a new J Code for ZUSDURI to streamline reimbursement, and a new loan agreement for up to $250 million.
URGN SEC Filings - Urogen Pharma 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides a comprehensive resource for Urogen Pharma (URGN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K material event reports, and insider trading forms. It aggregates regulatory disclosures for the Israel-organized biotechnology issuer listed on The Nasdaq Stock Market. The platform also offers AI-powered summaries, impact scoring, and sentiment analysis for each filing, helping investors quickly understand complex financial and governance information.
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
UroGen Pharma Ltd. announced the publication of pivotal Phase 3 ENVISION trial results for ZUSDURI in The Journal of Urology, showing a 72.2% probability of remaining event-free at 24 months for patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). This FDA-approved therapy, utilizing UroGen's RTGel® technology, offers a non-surgical alternative to repeated transurethral resection of bladder tumor (TURBT) procedures, addressing a significant unmet need for long-term management of this highly recurrent disease.
Urogen Pharma's (URGN) Buy Rating Reaffirmed at D. Boral Capital
D. Boral Capital has reaffirmed a "Buy" rating for Urogen Pharma (NASDAQ:URGN) with a $33 target price, indicating a potential upside of 94.12%. This aligns with the broader Wall Street consensus of a "Moderate Buy" with an average target of $33.29. Despite missing revenue estimates in the last quarter, the company beat EPS expectations, and institutional ownership remains high at 91.29%.
URGN: D. Boral Capital Maintains Buy Rating with $33 Price Targe
D. Boral Capital has reiterated its Buy rating on UroGen Pharma (URGN) with an unchanged price target of $33. This consistent rating, along with an "Outperform" consensus from other brokerage firms, reflects confidence in the company's market position and future potential. UroGen Pharma, a clinical-stage biotechnology firm, specializes in urothelial and specialty cancers, utilizing its RTGel technology to enhance drug delivery.
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
UroGen Pharma Ltd. announced the publication of pivotal Phase 3 ENVISION trial results for ZUSDURI™ (mitomycin) in The Journal of Urology. The study demonstrated a 72.2% probability of remaining event-free at 24 months after achieving a complete response at three months in adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). ZUSDURI, the first FDA-approved therapy for this condition, offers a non-surgical treatment potentially breaking the cycle of repeated recurrences and surgeries.
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
UroGen Pharma Ltd. announced the publication of pivotal Phase 3 ENVISION trial results for ZUSDURI™ in The Journal of Urology, demonstrating a 72.2% probability of remaining event-free at 24 months for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). ZUSDURI, an FDA-approved non-surgical treatment, showed a 79.6% complete response rate at three months, offering a significant and durable alternative to repeated surgical procedures for this highly recurrent condition. The company highlights ZUSDURI's potential to break the cycle of frequent recurrences and surgeries for bladder cancer patients.
Bladder cancer drug kept 72.2% of responders event-free for 2 years
UroGen Pharma announced the publication of Phase 3 ENVISION trial results for its drug ZUSDURI in The Journal of Urology. The data showed that 72.2% of patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) remained event-free for 24 months after achieving a complete response. ZUSDURI is the first FDA-approved therapy for this condition, offering a non-surgical alternative to repeated TURBT procedures.
Urogen Pharma Ltd. Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
Urogen Pharma Ltd. announced the publication of pivotal Phase 3 ENVISION trial results for ZUSDURI in The Journal of Urology. The study demonstrated a 72.2% probability of remaining event-free at 24 months for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) after achieving a complete response. ZUSDURI offers a potential alternative to repeated surgical procedures for this patient population, with reported adverse reactions primarily mild to moderate.
UroGen’s Zusduri shows 72% event-free rate at 24 months
UroGen Pharma announced positive results from its Phase 3 ENVISION trial of Zusduri for non-muscle invasive bladder cancer, showing a 72.2% event-free rate at 24 months. Despite a recent stock decline year-to-date, shares have surged over the past year due to Zusduri's commercial success, and analysts view the stock as undervalued. The drug, which has a remarkable gross profit margin, addresses an important medical need by providing an alternative to surgery for a condition with high recurrence rates.
URGN PE Ratio & Valuation, Is URGN Overvalued
Urogen Pharma Ltd (URGN) is currently considered undervalued, with its fair price estimated between $119.11 and $126.49, significantly higher than its current price of $17.17. The company's current forward P/S ratio of 5.26 is deemed undervalued compared to its five-year average. Despite a P/S ratio above the industry average, its robust revenue growth of 54.03% suggests this premium is sustainable.
Urogen Pharma $URGN Shares Acquired by JPMorgan Chase & Co.
JPMorgan Chase & Co. significantly increased its stake in Urogen Pharma (NASDAQ:URGN) in Q3, buying an additional 144,181 shares to bring its total to 534,545 shares, valued at approximately $10.66 million. Institutional investors collectively own about 91.29% of the company, with other notable increases from Paradigm Biocapital Advisors LP and Orbimed Advisors LLC. Despite recent insider selling, Urogen Pharma holds a "Moderate Buy" consensus rating from analysts with an average price target of $33.29.
SG Americas Securities LLC Purchases 220,264 Shares of Urogen Pharma $URGN
SG Americas Securities LLC significantly increased its stake in Urogen Pharma (NASDAQ:URGN) by 19.0% in Q4, acquiring 220,264 additional shares, bringing its total ownership to 1,377,647 shares valued at $32.26 million. Other institutional investors also adjusted their holdings, contributing to hedge funds and institutional investors owning 91.29% of the company's stock. Despite some insider selling, Urogen Pharma has a "Moderate Buy" consensus rating from analysts with an average price target of $33.29.
Urogen Pharma (NASDAQ:URGN) Given Average Recommendation of "Moderate Buy" by Analysts
Urogen Pharma (NASDAQ:URGN) has received an average "Moderate Buy" rating from analysts, with a 12-month average price target of $33.29, significantly higher than its recent share price of $18.12. The company recently reported Q4 EPS of ($0.54), beating estimates, though revenue missed consensus, and it remains unprofitable with an expected EPS of -3.12 for the current fiscal year. Insider selling and institutional buying have been noted, with insiders owning 4.70% and institutions holding 91.29% of the stock.
Veteran cancer researcher Mark joins Urogen Pharma to drive progress in urologic oncology
Urogen Pharma has appointed Mark, a distinguished expert in urothelial cancer, to lead its advancements in urologic oncology. With extensive clinical and academic experience, Mark is expected to accelerate research and development efforts. The company is committed to improving patient outcomes and recently participated in the SES AUA event to foster innovation and collaboration within the clinical community.
Live UroGen Pharma Ltd. (URGN) Technical Analysis
This article provides a live technical analysis of UroGen Pharma Ltd. (URGN) stock. It details real-time pricing, daily and weekly ranges, and presents a comprehensive technical indicator overview, largely showing "Neutral" signals across various timeframes for immediate trading decisions. The analysis also includes moving averages and other technical indicators, which collectively suggest a "Sell" forecast for URGN based on the summary of moving averages and technical indicators.
UroGen Pharma Ltd. (URGN) Stock Price Prediction: Today, Tomorrow, Next Week
This article provides a stock price prediction for UroGen Pharma Ltd. (URGN) for today, tomorrow, and next week, based on technical analysis and a proprietary forecasting model. It outlines expected daily and weekly price ranges, along with monthly forecasts, and indicates a current neutral outlook from various technical indicators. The report suggests a potential short-term decline for URGN, with a projected average price for the next trading day and weekly ranges for the upcoming month.
UroGen Pharma Ltd. (URGN) Stock Price Prediction for 2026, 2030-2040
This article provides detailed stock price predictions for UroGen Pharma Ltd. (URGN) for the years 2026, and further out to 2030-2040, based on various statistical models and analyst consensus. It includes monthly forecasts for 2026, annual projections for future decades, market capitalization history, and an overview of current analyst recommendations and earnings forecasts. The report emphasizes that these forecasts are for informational purposes and highlight the inherent risks of financial markets.
UroGen Pharma Ltd Stock (ISIN: IL0011408896) Faces Pressure Amid Clinical Setbacks and Cash Burn Concerns
UroGen Pharma Ltd (ISIN: IL0011408896), a Nasdaq-listed biotech, is experiencing stock pressure after its Phase 3 trial for UGN-102 met its primary endpoint but showed less durability than expected, raising concerns about its regulatory path and peak sales estimates. Amid these clinical setbacks, the company also faces scrutiny over its cash burn rate, with investors reassessing its risk-reward profile, particularly given its reliance on existing commercial product Jelmyto to fund its pipeline and ongoing market volatility in the small-cap biotech sector. European investors are closely watching for FDA feedback and potential dilution risks as the commercialization timeline for UGN-102 shifts.
UroGen Pharma Ltd Stock (ISIN: IL0011408896) Faces Pressure Amid Clinical Setbacks and Cash Burn Concerns
UroGen Pharma Ltd stock has declined by approximately 15% following disappointing Phase 3 trial results for its key urology drug candidate, UGN-102, which met its primary endpoint but fell short on durability expectations. This setback, combined with ongoing cash burn concerns and a crowded competitive landscape, has put pressure on the Nasdaq-listed biotech. Investors are reassessing the company's risk-reward profile, with a focus on potential label limitations for UGN-102 and the implications for its commercialization timeline and financial health.
UroGen Pharma Ltd Stock (ISIN: IL0011408896) Faces Pressure Amid Biotech Sector Volatility
UroGen Pharma Ltd's stock is experiencing volatility as investors scrutinize its clinical progress and cash burn within a challenging biotech funding landscape, particularly for urology-focused companies. Despite its lead product Jelmyto and late-stage candidate UGN-102, the company faces pressure to demonstrate clinical milestones and manage its cash runway, with upcoming ENVISION trial data being a critical catalyst. European investors are watching closely due to the high incidence of bladder cancer in the region and the potential for EMA approval.
UroGen Pharma Ltd Stock (ISIN: IL0011408896) Faces Pressure Amid Biotech Sector Volatility
UroGen Pharma Ltd (ISIN: IL0011408896), a Nasdaq-listed biotech specializing in therapies for urothelial cancers, is experiencing volatility due to broader sector pressures and tight funding markets. The company's lead product, Jelmyto, generates revenue, and its investigational candidate UGN-102 is in late-stage development, with key clinical data expected mid-2026. European investors are monitoring its cash position and clinical milestones, with potential for EMA filing adding diversification appeal despite financial risks like dilution and R&D burn.
Bladder cancer survey: 80% of patients live with fear it will return
UroGen Pharma highlighted findings from the Bladder Cancer Advocacy Network's (BCAN) new report, which surveyed over 1,100 bladder cancer patients in the U.S. The report revealed that nearly 80% of patients fear recurrence, with this figure rising to over 90% for those under 50. It also shed light on the significant procedural burden, with many patients undergoing multiple cystoscopies.
UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence
UroGen Pharma Ltd. has praised the Bladder Cancer Advocacy Network's (BCAN) new "The New Faces of Bladder Cancer Report," which reveals the significant burden of recurrence and fear of recurrence among bladder cancer patients. The national survey of over 1,100 patients showed that nearly 80% fear recurrence, with this figure rising to over 90% for those under 50. The report also highlights the high number of medical procedures patients undergo, with many reporting five or more cystoscopies.
URGN Stock Price, Quote & Chart | UROGEN PHARMA LTD (NASDAQ:URGN)
This article provides a detailed overview of UROGEN PHARMA LTD (NASDAQ:URGN) stock performance, key statistics, and analyst forecasts. The stock closed at $18.44 on March 13, 2026, and analysts predict a significant price increase of 94.98% in the next year. The company's technical and fundamental ratings are low, but it has shown strong long-term performance and focuses on developing solutions for urothelial and specialty cancers.
TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $35
TD Cowen analyst Tara Bancroft has reiterated a Buy rating for UroGen Pharma Ltd (URGN.US) and maintained a target price of $35. According to TipRanks data, this analyst has a 47.4% success rate and an average return of 24.6% over the past year. This information is provided for educational purposes and is not an investment recommendation.
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd. announced the grant of inducement restricted stock units (RSUs) to 11 new employees to support the commercialization of JELMYTO® and ZUSDUR™ and the development of its pipeline. Up to 51,200 ordinary shares are issuable upon vesting of these RSUs over three years. These grants were made under Nasdaq Listing Rule 5635(c)(4) as a material inducement for employment.
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd. announced the grant of restricted stock units (RSUs) to 11 new employees as an inducement for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4). These grants are intended to support the commercialization of UroGen's approved products, JELMYTO® and ZUSDURI™, and the development of its pipeline. Up to 51,200 ordinary shares are issuable upon the vesting of these RSUs over three years.
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd. announced the grant of inducement restricted stock units (RSUs) to 11 new employees to support the commercialization of its approved products, JELMYTO and ZUSDURI, and the development of its pipeline. Up to 51,200 ordinary shares are issuable upon the vesting of these RSUs over three years, subject to continued employment. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).
UroGen grants 51,200 stock units to new hires backing cancer drugs
UroGen Pharma announced the grant of 51,200 restricted stock units (RSUs) to 11 new employees on March 6, 2026, as an inducement for their employment. These RSUs will vest equally over three years and are intended to support the commercialization of UroGen's approved cancer drugs, JELMYTO and ZUSDUR, and the continued development of its pipeline. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) and reflect the company's ongoing strategy of equity-based compensation to attract talent.
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd. announced inducement restricted stock units (RSUs) grants to 11 new employees, enabling them to receive up to 51,200 ordinary shares. These grants are intended to support the commercialization of JELMYTO® and ZUSDURI™ and the development of UroGen's pipeline. The RSUs vest over three years, contingent on continued employment, and were issued in accordance with Nasdaq Listing Rule 5635(c)(4).
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd. announced the grant of inducement restricted stock units (RSUs) to 11 new employees to support the commercialization of its approved products, JELMYTO and ZUSDUR, and the development of its pipeline. Up to 51,200 ordinary shares will be issuable upon the vesting of these RSUs, which will vest equally over three years. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as a material inducement for their employment.
JPMorgan Chase & Co. Buys 144,181 Shares of Urogen Pharma $URGN
JPMorgan Chase & Co. increased its holdings in Urogen Pharma by 36.9% in the third quarter, acquiring an additional 144,181 shares, bringing its total to 534,545 shares valued at approximately $10.66 million. Despite strong institutional ownership at 91.29% and a recent EPS beat, insiders like Mark Schoenberg and the General Counsel have been selling shares. The company faces mixed analyst sentiment, with a "Moderate Buy" average rating but also substantial lowering of near-term EPS estimates by some analysts.
Assessing UroGen Pharma (URGN) Valuation After Recent Share Price Volatility
UroGen Pharma (URGN) has seen recent stock volatility, closing at $20.16 after a 7.1% daily gain, but with mixed short-term returns. Despite this, the company is considered undervalued with an analyst price target of $35.63 and a higher intrinsic value due to its focus on minimally invasive therapies and potential for improved net margins. However, ongoing operating losses and concentrated revenue present risks to this optimistic outlook.
UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers
UroGen Pharma is at a critical juncture with its newly approved bladder cancer therapy, ZUSDURI, expected to see rapid adoption and achieve $1 billion in peak sales by 2030, driven by a permanent J-Code in 2026. Despite an improved liquidity of $245.5 million, high cash burn necessitates ZUSDURI's commercial success for financial stability. Key risks include market adoption, management execution, and patent expirations starting in 2028.
UroGen’s ZUSDURI Data And Reimbursement Progress Shift Risk Reward Profile
UroGen Pharma's ZUSDURI has shown durable complete response rates in Phase 3 trials for recurrent non-muscle invasive bladder cancer, offering a non-surgical option. The activation of a permanent J code on January 1, 2026, is improving reimbursement and patient access, leading to increased adoption. While the company faces ongoing net losses and high operating costs, the clinical data and reimbursement clarity are key factors for investors to monitor regarding its commercial success and future revenue growth.
UroGen Pharma Secures New $250 Million Term Loan
UroGen Pharma has finalized a new loan agreement for up to $250 million, securing $200 million upfront and having access to an additional $50 million through June 2027. This loan refinances an existing $125 million debt, extends their funding runway, and carries an 8.25% fixed interest rate with maturity in five years. While enhancing liquidity and postponing principal repayments, the agreement includes strict covenants and prepayment penalties, signaling a focus on capital protection by lenders.
UroGen Pharma Earnings Preview
UroGen Pharma (NASDAQ: URGN) is preparing to release its quarterly earnings report. Analysts estimate an EPS of $-0.57, and investors are keenly awaiting both the results and guidance for the upcoming quarter. The company has a mixed past earnings performance, but its shares have shown significant growth over the last 52 weeks.
UroGen Pharma (NASDAQ: URGN) inks $250M secured term loan deal
UroGen Pharma has finalized a secured term loan agreement for up to $250 million. The company immediately received a $200 million Tranche A loan to refinance existing debt and fund corporate needs, with an additional $50 million (Tranche B) available until June 2027. This five-year loan carries a fixed annual interest rate of 8.25%, with principal repayment starting in 2030, and is secured by substantially all of UroGen's assets.
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
UroGen Pharma Ltd. announced its fourth quarter and full year 2025 financial results, highlighting the on-track commercial launch of ZUSDURI, with $15.8 million in net sales for 2025 and a permanent J Code becoming effective in January 2026. The company also reported JELMYTO's net product sales of $94 million in 2025 and provided updates on its pipeline, including UGN-103 and UGN-104, alongside a refinancing of its term loan with Pharmakon Advisors. UroGen maintains its full-year 2026 JELMYTO sales guidance and operating expense projections.
UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2025 Earnings Call Transcript
UroGen Pharma Ltd. reported strong Q4 2025 earnings, beating expectations with an EPS of $-0.53552. The company highlighted the successful early 2026 launch trajectory of Zasturi, its recurrent low-grade, intermediate-risk non–muscle invasive bladder cancer treatment, following the effectiveness of its permanent J code, and anticipates it could achieve over $1 billion in peak revenue. UroGen Pharma also discussed the continued demand for Jelmyto, refinancing its debt facility, and significant progress in its pipeline, including UGN-103 and UGN-501.
Urogen Pharma Q4 2025 Earnings Call Transcript
Urogen Pharma reported Q4 2025 financial results, highlighting strong initial traction for its ZUSDURI launch following the permanent J-code implementation and continued demand for JELMYTO. The company also announced a successful refinancing of its term loan, providing enhanced financial flexibility. While significant net losses were reported for 2025, Urogen projects over $1 billion in potential peak revenue for ZUSDURI and provided 2026 revenue guidance for JELMYTO, along with updates on its robust pipeline, including UGN-103 and UGN-501.
UroGen Pharma (URGN) Quarterly Loss Narrows To US$0.54 EPS Challenging Bearish Narratives
UroGen Pharma (URGN) reported a narrowed Q4 FY 2025 loss of US$0.54 EPS, with quarterly revenue reaching US$37.8 million, showing strong top-line momentum. Despite this, the company still faces significant net losses (US$153.5 million for TTM) and negative equity, leading to conflicting bullish and bearish narratives. While forecasts predict future growth and profit margins, current financial figures highlight ongoing challenges in achieving profitability, with the balance sheet showing a cash runway of less than one year.
Oppenheimer Maintains Outperform on UroGen Pharma Ltd. (URGN) March 2026
Oppenheimer has reiterated an Outperform rating for UroGen Pharma Ltd. (URGN) on March 2, 2026, viewing the stock's recent decline as a buying opportunity. The firm did not issue a new price target, implying continued confidence in UroGen's pipeline and commercial progress without a fresh catalyst for a higher rating. This maintained rating follows UroGen's full-year 2025 results and an ambitious $1 billion peak revenue target for ZUSDURI.
Akin Advises Pharmakon in $250 Million Term Loan Financing for UroGen Pharma
Akin advised Pharmakon Advisors, LP and its affiliated funds in providing a senior secured term loan of up to $250 million to UroGen Pharma Ltd., a biotech company focusing on urothelial and specialty cancers. The financing includes an initial $200 million tranche to refinance existing debt and provide non-dilutive capital. The Akin team was led by tax partners Geoffrey Secol and Stuart Leblang, and healthcare & life sciences partner Nathan Brown, along with senior counsel Jo-Ellyn Klein and counsel Emily Gerry and Caroline Kessler.
Urogen Pharma Ltd reports results for the quarter ended December 31 - Earnings Summary
Urogen Pharma Ltd has released its earnings summary for the quarter that concluded on December 31. The report, published by Refinitiv and relayed via Reuters, provides key financial information for the Israeli pharmaceutical company, whose stock symbol is URGN.
UroGen Pharma Ltd. Enhances Financial Position with Amended Loan Agreement for Up to $250 Million
UroGen Pharma Ltd. has finalized a new loan agreement with Pharmakon Advisors, LP, securing up to $250 million. This refinancing effort includes an initial $200 million tranche at an 8.25% fixed interest rate to refinance existing debt and provide additional capital, with an option for an extra $50 million. The agreement extends the loan maturity to Q1 2030 and features no financial covenants, aimed at enhancing UroGen's financial flexibility and supporting its long-term growth strategy.
UroGen Pharma (URGN) outlines RTGel cancer platform, Jelmyto, Zusduri and pipeline
UroGen Pharma has filed its annual report, detailing its uro-oncology strategy centered on the RTGel drug-delivery platform. The company's approved products, Jelmyto and Zusduri, utilize RTGel to deliver mitomycin for the non-surgical treatment of low-grade upper tract urothelial carcinoma and recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, respectively. UroGen's pipeline includes next-generation mitomycin products and an investigational oncolytic virus (UGN-501) for high-grade disease, emphasizing patent protection and regulatory expertise.
UroGen Pharma (URGN) grows 2025 revenue 21% as ZUSDURI launch ramps
UroGen Pharma reported a 21% increase in 2025 revenue, reaching $109.8 million, primarily driven by the commercial launch of its bladder cancer drug ZUSDURI and continued growth of JELMYTO. Despite this revenue growth, the company's net loss widened to $153.5 million due to increased R&D and selling, general, and administrative expenses. UroGen anticipates 2026 to be a pivotal year for ZUSDURI's rollout, projecting JELMYTO net product sales of $97–$101 million and operating expenses between $240–$250 million, while advancing its late-stage pipeline candidates UGN-103 and UGN-104.
UroGen Pharma: Q4 Earnings Insights
UroGen Pharma (NASDAQ: URGN) announced its Q4 earnings on March 2, 2026, beating estimated earnings per share (EPS) by 5.26% with an EPS of $-0.54 against an estimate of $-0.57. The company's revenue also recorded a significant increase of $13.27 million compared to the previous year. This report provides key financial figures and past performance insights for investors.
